Fatty Liver Disease Along Cushing Syndrome Evolution
Authors' conclusion
We estimated the prevalence of hepatic steatosis at the diagnosis of Cushing syndrome at 26.5%. The presence of metabolic factors was associated with the occurrence of hepatic steatosis.
Study context
- Population
- Patients followed for CS with available abdominal imaging at diagnosis, Angers Hospital (France), 2010–2020
- Participants
- 49 patients
- Outcome
- Prevalence of MASLD at diagnosis of CS (hepatic steatosis: mean liver/spleen density ratio < 1 on CT)
- Follow-up
- Diagnosis of CS
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Hepatic steatosis at diagnosis of CS
Hepatic steatosis
13
26.5%
All patients with hepatic steatosis had MASLD
13
Observational data: associations, not effects.
Further findings
Factors associated with hepatic steatosis
- Higher prevalence of T2D and higher TG levels in patients with steatosis (multivariate analysis)
- No difference according to intensity or duration of CS
Significant fibrosis predictive score among MASLD patients
- Significant fibrosis predictive score (of 13 with MASLD)
- 2 (15.4%)
Steatosis after remission of CS · 1–5 years after remission
- Remission of steatosis among 4 patients with follow-up imaging
- 3
- Patients without MASLD at diagnosis with worsening liver/spleen ratio after remission
- 0
Original publication
Fatty Liver Disease Along Cushing Syndrome Evolution. J Clin Endocrinol Metab. Published 28 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →